Result of AGM

Nuformix PLC
19 March 2024
 

Nuformix plc

("Nuformix" or the "Company")

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual General Meeting ("AGM") of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved by way of a poll vote.  The results of the poll, including proxies received ahead of the AGM, are reported below:

 

Resolution

Ordinary/ Special

For

 

Against

 

Total votes cast




No. of votes

%

No. of votes

%


1

To receive the annual report and accounts for the year ended 30 September 2023

 

Ordinary

142,381,407

97.38%

3,824,784

2.62%

146,206,191

2

To approve the annual report on remuneration

 

Ordinary

142,812,526

97.60%

3,505,839

2.40%

146,318,365

3

To re-appoint Daniel Gooding as a director

 

Ordinary

141,901,631

97.81%

3,179,490

2.19%

145,081,121

4

To re-appoint Julian Gilbert as a director

 

Ordinary

141,901,631

97.81%

3,179,490

2.19%

145,081,121

5

To re-appoint Madeleine Kennedy as a director

 

Ordinary

141,881,631

97.75%

3,270,050

2.25%

145,151,681

6

To re-appoint Kreston Reeves LLP as auditor

 

Ordinary

142,139,182

97.90%

3,055,316

2.10%

145,194,498

7

To authorise the directors to determinethe auditor's fees

 

Ordinary

141,874,740

97.71%

3,319,758

2.29%

145,194,498

8

To authorise the directors to allot shares

 

Ordinary

136,385,306

93.95%

8,785,230

6.05%

145,170,536

9

To authorise the directors to disapply pre-emption rights

 

Special

134,565,189

92.73%

10,553,347

7.27%

145,118,536

10

To authorise the Company to purchase its own shares

 

Special

135,812,749

94.11%

8,504,877

5.89%

144,317,626

11

To authorise calling of a general meeting on 14 clear days' notice

 

Special

142,106,241

97.84%

3,141,610

2.16%

145,247,851

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 819,309,368 ordinary shares of £0.001 each.

Enquiries:

 

Nuformix plc

 

Dr Dan Gooding, Executive Director

 

Via IFC Advisory

 

Stanford Capital Partners Limited


Tom Price / Patrick Claridge (Corporate Finance)

+44 (0) 20 3650 3650

Bob Pountney (Corporate Broking)

+44 (0) 20 3650 3652

 

IFC Advisory Limited


Tim Metcalfe

Zach Cohen

+44 (0) 20 3934 6630

nuformix@investor-focus.co.uk

               

 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

 

For more information, please visit www.nuformix.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Nuformix (NFX)
UK 100

Latest directors dealings